Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers

Article English OPEN
Ahmad, Dena A. J. ; Negm, Ola H. ; Alabdullah, M. Layth ; Mirza, Sameer ; Hamed, Mohamed R. ; Band, Vimla ; Green, Andrew R. ; Ellis, Ian O. ; Rakha, Emad A. (2016)
  • Publisher: Springer Nature
  • Journal: Breast Cancer Research and Treatment, volume 159, issue 3, pages 457-467 (issn: 0167-6806, eissn: 1573-7217)
  • Related identifiers: doi: 10.1007/s10549-016-3967-9, pmc: PMC5021722
  • Subject: Reverse phase protein microarray (RPPA) | MAPK signalling pathways | Breast cancer | Preclinical Study | Cancer Research | Oncology

Background Mitogen-activated protein kinases (MAPKs) are signalling transduction molecules that have different functions and diverse behaviour in cancer. In breast cancer, MAPK is related to oestrogen receptor (ER) and HER2. Methods Protein expression of a large panel of MAPKs (JNK1/2, ERK, p38, C-JUN and ATF2 including phosphorylated forms) were assessed immunohistochemically in a large (n = 1400) and well-characterised breast cancer series prepared as tissue microarray. Moreover, reverse phase protein array was applied to quantify protein expression of MAPKs in six breast cancer cell lines with different phenotypes including HER2-transfected cells. Results MAPKs expression was associated with clinicopathological variables characteristic of good prognosis. These associations were most significant in the whole series and in the ER+ subgroup compared to other BC classes. Most of MAPKs showed a positive association with ER, BCL2 and better outcome and were negatively associated with the proliferation marker Ki67 and p53. Association of MAPK with HER2 was mainly seen in the ER- subgroup. Reverse phase protein array confirmed immunohistochemistry results and revealed differential expression of MAPK proteins in ER+ and ER− cell lines. Conclusions MAPKs are associated with good prognosis and their expression is mainly related to ER. Studying a large panel rather than individual biomarkers may provide improved understanding of the pathway. Electronic supplementary material The online version of this article (doi:10.1007/s10549-016-3967-9) contains supplementary material, which is available to authorized users.
  • References (54)
    54 references, page 1 of 6

    1. Dhillon AS et al (2007) MAP kinase signalling pathways in cancer. Oncogene 26(22):3279-3290

    2. McCubrey JA et al (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773(8):1263-1284

    3. Chappell WH et al (2011) Ras/Raf/MEK/ERK and PI3K/PTEN/ Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2(3):135-164

    4. Neel NF et al (2011) The RalGEF-Ral effector signaling network: the road less traveled for anti-ras drug discovery. Genes Cancer 2(3):275-287

    5. Rajalingam K et al (2007) Ras oncogenes and their downstream targets. Biochim Biophys Acta 1773(8):1177-1195

    6. Ramos JW (2008) The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 40(12):2707-2719

    7. Johannessen CM et al (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326):968-972

    8. Schaeffer HJ, Weber MJ (1999) Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19(4):2435-2444

    9. Kyriakis JM, Avruch J (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81(2):807-869

    10. Karin M, Gallagher E (2005) From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 57(4-5):283-295

  • Related Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark